Increasing Prevalence of Cancer Worldwide
Cancer is a leading cause of death worldwide. WHO estimates that there were 8.2 million deaths to cancer, in 2012, with lung cancer claiming the most lives (1.59 million), followed by liver (745,000 deaths), stomach (723,000 deaths), colorectal (694,000 deaths), breast (521,000 deaths) and esophageal cancer (400 000 deaths) across the world. According to the estimated provided by The World Cancer Report 2014, from the World Health Organization's (WHO's) International Agency for Research on Cancer (IARC), the global burden of cancer will rise from an estimated 14 million new cases per year in 2012 to 22 million within the next 20 years. Developing countries are disproportionately affected by the growing numbers of cancers due to growing and aging populations. Hence the increasing number of cancer cases and the increasing need to treat them effectively and efficiently is going to help boost the market for doxorubicin in the forecast period.
Other factors driving the market growth are increasing application of doxorubicin and an increasing number of companies manufacturing doxorubicin.
Side Effects Associated With Doxorubicin
Doxorubicin is cancer (antineoplastic) medication used to treat many types of cancer. Common side effects of doxorubicin include nausea and vomiting (may be severe), diarrhea, loss of appetite, missed menstrual periods, darkening of skin or nails, weakness, tiredness, eye redness, or puffy eyelids. Adriamycin PFS (doxorubicin hydrochloride) may give tears, sweat that may last up to several days and a reddish color to urine. There might be serious side effects including cough, hoarseness, persistent diarrhea, redness, flushing of face, eye itching, unusual tiredness, joint pain, pain in the lower back/side/stomach/abdomen, painful or difficult urination, black/tarry stools, bloody mucus or discharge in stools, fast or irregular heartbeat, shortness of breath, dizziness, swelling of ankles or feet, or decreased urination. Doxorubicin can also interact with paclitaxel, progesterone, verapamil, cyclosporine, cyclophosphamide, phenobarbital, phenytoin, streptozocin, or "live" vaccines. Hence the side effects associated with the use of Doxorubicin may hinder its usage and can act as a restraining factor for the market.
North America is expected to dominate the Market
North America is expected to dominate the market throughout the forecast period. The growing number of cancer cases and subsequently increasing usage of the doxorubicin in mono and combination chemotherapies are going to impact the market. Moreover, the increasing number of mergers and acquisitions and partnerships for clinical trials with technologically advanced doxorubicin formulations is one of the crucial factors driving the market in this region.
Key Developments in the Market:
Aug 2018: India, Hyderabad-based NATCO Pharma Ltd has announced that its co-development and marketing partner, Dr Reddy’s Laboratories Ltd, has filed for registration of doxorubicin hydrochloride liposome injection for intravenous use, in the European markets.
Major Players: Cadila Pharmaceuticals, Cipla, Inc., Janssen Products LP, Pfizer Inc., SRS Pharmaceuticals Pvt. Ltd. and Sun Pharmaceutical Industries Ltd. among others.
Reasons to Purchase this Report
Current and future Doxorubicin market outlook in the developed and emerging markets
Analyzing various perspectives of the market with the help of Porter’s five forces analysis
The segment that is expected to dominate the market
Regions that are expected to witness the fastest growth during the forecast period
Identify the latest developments, market shares and strategies employed by the major market players
3-month analyst support along with the Market Estimate sheet (in Excel)
Customization of the Report
This report can be customized to meet your requirements. Please connect with our representative, who will ensure you to get a report that suits your needs.
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry within the Industry
6. Market Dynamics
6.1.1 Increasing number of companies manufacturing doxorubicin
6.1.2 Increasing application of doxorubicin
6.1.3 Increasing prevalence of cancer worldwide
6.2.1 Supply-demand gap
6.2.2 Side effects associated with Doxorubicin
7. Market Segmentation
7.1 By Drug Formulation
7.1.1 Lyophilized Powder
7.1.2 Doxorubicin Injection
7.2 By Application
7.2.1 Bladder Cancer
7.2.2 Kaposi Sarcoma
7.2.5 Breast cancer
7.3 By Distribution Channel
7.3.1 Hospital Pharmacy
7.3.2 Retail Pharmacy
7.3.3 Online Pharmacy
7.4 By Geography
7.4.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
7.4.4 Middle East & Africa
220.127.116.11 South Africa
18.104.22.168 Rest of the Middle East & Africa
7.4.5 South America
22.214.171.124 Rest of South America
8. Company Profiles and Competitive Landscape
8.1 Cadila Pharmaceuticals
8.2 Cipla, Inc.
8.3 Janssen Products, LP
8.4 Pfizer, Inc.
8.5 SRS PHARMACEUTICALS PVT. LTD.
8.6 Sun Pharmaceutical Industries Ltd.
* List Not Exhaustive
9. Future Outlook of the Market